Vesalius Cardiovascular Inc.

Vesalius Cardiovascular Inc. is a Canadian medical device company based in Vancouver, founded in 2016. The company specializes in developing innovative, non-invasive transfemoral devices aimed at treating degenerative mitral regurgitation (MR), a common cardiovascular condition. Vesalius focuses on therapies for structural heart disease, particularly targeting the treatment of degenerative MR, which affects a significant portion of the population.

The company is currently developing the Calla system, a transfemoral mitral valve repair device that applies surgical repair principles in a minimally invasive manner. This system is designed to enable individualized repairs in a standardized procedure, potentially streamlining the intervention process. Vesalius is in the pre-clinical phase and is preparing for an FDA early feasibility study and first-in-human procedures in early 2025. The leadership team includes co-founder and CEO Vincent Ledoux, along with Dr. Peter Skarsgard, who is also a co-founder and serves as the Chief Medical Officer.